Jagsonpal Pharmaceuticals Limited

BSE: JAGSNPHARM507789ISIN INE048B01035

Healthcare
Pharmaceuticals
BSE Healthcare

Share price

₹221.80+5.00 (+2.31%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

Splits and bonuses

8 Jan 2025 · Split 2.5:1 (₹5 → ₹2)

52W high: ₹264.65
52W low: ₹154.90
Off 52W high: -16.19%
1M return: -3.33%
3M return: -7.14%
6M return: +5.87%
1Y return: +2.16%
20D avg volume: 5,347
50 DMA: ₹229.84
200 DMA: ₹208.51

Key ratios Consolidated

Market cap: ₹1,465 Cr
Current price: ₹221.80
52W high / low: ₹264.65 / ₹154.90
Face value: ₹2.00
P/E: 0.00
P/B: 6.09
EPS (TTM): ₹0.00
Book value / share: ₹36.42
ROE: —
ROCE: —
Operating margin: —
Net margin: —
Debt / equity: —
Net debt: —
Interest cover: —
Dividend yield: 1.80%
Dividend / share (TTM): ₹4.00
Payout: —
Cash conversion cycle: —

Financials

Metric	Q2 FY27	Q4 FY26
Income statement
	96.37	—
	2.25	—
	98.62	—
	81.97	—
	4.68	—
	35.86	—
	23.33	—
	0.29	—
	2.21	—
	15.18	—
	16.65	—
	-0.23	—
	16.42	—
	4.13	—
	12.29	—
	1.86	—
Key metrics
	18.92	—
	19.60%	—
	12.80%	—
	6.30%	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	81.38	82.23	64.20	72.94	74.47	75.61	58.56	74.03	74.69	61.44	43.49	47.23
	2.23	2.83	3.17	2.98	3.03	2.83	2.77	2.32	1.65	1.44	2.49	2.52
	83.61	85.06	67.37	75.92	77.49	78.44	61.33	76.35	76.35	62.88	45.97	49.76
	66.54	67.39	55.62	59.32	60.68	64.01	52.41	60.86	60.98	52.49	41.44	44.48
	4.68	4.87	2.99	3.95	3.84	5.33	3.48	5.27	5.20	4.39	3.79	5.88
	25.30	26.05	19.89	22.81	23.80	22.69	17.50	21.12	22.03	20.03	12.06	14.15
	22.00	22.78	15.54	17.58	18.18	19.44	16.57	18.08	16.68	14.74	11.45	11.64
	0.25	0.25	0.25	0.26	0.27	0.25	0.26	0.26	0.23	0.21	0.22	0.23
	1.68	2.14	2.32	2.39	2.39	2.35	2.31	2.41	2.34	1.07	0.40	0.41
	13.42	13.59	13.73	12.64	12.63	15.03	11.56	13.59	13.25	11.73	9.43	9.80
	17.06	17.68	11.76	16.60	16.81	14.43	8.92	15.49	15.37	10.39	4.54	5.28
	-0.23	0.00	0.00	-2.08	0.00	0.00	-0.21	23.18	—	-3.29	—	—
	16.83	17.68	11.76	14.52	16.81	14.43	8.71	38.67	15.37	7.11	4.54	5.28
	4.24	4.49	2.99	3.57	4.24	3.64	2.12	6.68	3.91	1.78	0.99	1.32
	12.59	13.19	8.76	10.95	12.57	10.79	6.58	31.99	11.46	5.33	3.55	3.96
	1.91	2.00	1.25	1.67	1.88	1.60	0.98	4.74	4.29	1.94	1.31	1.48
Key metrics
	18.76	20.07	14.33	17.17	19.47	17.03	11.28	41.34	17.94	8.39	5.16	5.92
	23.10%	24.40%	22.30%	23.50%	26.10%	22.50%	19.30%	55.80%	24.00%	13.70%	11.90%	12.50%
	15.50%	16.00%	13.60%	15.00%	16.90%	14.30%	11.20%	43.20%	15.30%	8.70%	8.20%	8.40%
	6.70%	—	4.20%	—	6.40%	—	3.60%	—	—	—	—	—
	9.30%	8.80%	9.60%	-1.50%	-0.30%	23.10%	34.70%	56.70%	—	—	—	—
	0.20%	22.20%	33.10%	-65.80%	9.70%	102.40%	85.40%	707.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	300.75	287.23	268.72	208.70	236.71	226.10
	11.21	11.99	8.19	9.28	5.73	3.34
	311.96	299.22	276.91	217.98	242.45	229.43
	248.87	239.62	226.73	188.11	204.18	202.11
	16.49	16.11	18.34	22.10	31.21	40.42
	94.05	89.19	80.22	53.98	57.59	49.75
	77.90	70.74	70.93	48.49	56.41	57.68
	1.01	1.03	0.96	0.81	0.41	0.29
	8.53	9.44	8.13	1.66	1.21	1.53
	53.38	54.04	50.27	43.85	44.28	46.84
	63.10	59.60	50.17	29.87	38.27	27.32
	-2.31	-2.08	19.69	—	-3.46	—
	60.79	57.52	69.86	29.87	34.81	27.32
	15.29	14.44	14.50	7.41	8.09	7.73
	45.49	43.08	55.36	22.46	26.72	19.59
	6.83	6.40	8.26	8.49	10.20	7.48
Key metrics
	70.33	67.99	78.95	32.34	36.43	29.14
	23.38%	23.70%	29.40%	15.50%	15.40%	12.90%
	15.13%	15.00%	20.60%	10.80%	11.30%	8.70%
	—	20.30%	28.10%	—	—	—
	6.40%	6.90%	28.80%	-11.80%	4.70%	—
	-26.55%	-22.20%	146.50%	-15.90%	36.40%	—
	—	46.81	54.95	—	—	—
	—	1.09	1.00	—	—	—
	—	0.00	0.00	—	—	—
	—	-10.04	-11.21	—	—	—
	—	25.7	25.3	—	—	—
Balance sheet
	—	316.68	278.26	—	—	—
	—	143.09	161.19	—	—	—
	—	10.04	11.21	—	—	—
	—	17.19	13.18	—	—	—
	—	14.64	15.20	—	—	—
	—	5.07	4.02	—	—	—
	—	0.57	0.61	—	—	—
	—	11.58	9.73	—	—	—
	—	28.30	25.90	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	276.17	239.95	—	—	—
Cash flow
	—	46.81	55.30	—	—	—
	—	-35.65	-45.15	—	—	—
	—	-12.15	-11.70	—	—	—
	—	0.00	0.35	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +6.66%
Sales CAGR 5Y: —
Profit CAGR 3Y: +17.26%
Profit CAGR 5Y: —
Sales YoY (TTM): +6.40%
Profit YoY (TTM): -26.55%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 68.83%

Quarter	30 Sep 2026	September 2026	June 2026
Promoter %	68.83%	68.83%	69.06%

Holder	Type	Holding	Previous	Change
Aresko Progressive Private Limited (Trustee of Aresko Progressive Trust, in the capacity of representative) partner of J&P Investments Partnership)	Promoter	20.19%	20.19%	0.00%
INFINITY CAPITAL (Formerly Infinity Holdings Sidecar1)	Promoter Group	18.00%	18.00%	0.00%
INFINITY HOLDINGS	Promoter Group	16.70%	16.70%	0.00%
INFINITY PORTFOLIO HOLDINGS	Promoter Group	8.66%	8.66%	0.00%
RAJPAL SINGH KOCHHAR	Promoter	4.59%	4.59%	0.00%
MANISH GUPTA	Public	3.18%	3.18%	0.00%
INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRS	Public	1.49%	1.49%	0.00%
AUTHUM INVESTMENT AND INFRASTRUCTURE LIMITED	Public	1.47%	1.47%	0.00%
LINCOLN P COELHO	Public	1.17%	1.17%	0.00%
Prithipal Singh Kochhar	Promoter Group	0.41%	0.41%	0.00%
Inderpal Singh Kochhar	Promoter Group	0.28%	0.28%	0.00%
Aresko Global LLP	Promoter Group	0.00%	0.00%	0.00%
RPSK Partners LLP	Promoter Group	0.00%	0.00%	0.00%
Jaswant Singh Kochhar Foundation	Promoter Group	0.00%	0.00%	0.00%
Aresko Estates Private Limited	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Jagsonpal Pharmaceuticals Limited S	1,465	221.80	32.19	20.30%	+6.40% TTM	-26.55% TTM	+2.16%

Filings & corporate actions

Recent announcements

Earning call transcript for Jagsonpal Pharmaceuticals Limited Q2 FY 27 Earning Conference Call on October 29, 2026 at 2:00 P.M3 Nov 2026 · Company Update / Earnings Call Transcript
Audio Recording of Jagsonpal Pharmaceuticals Limited Q2 FY27 Earnings Conference call on October 29, 2026 at 02:00 P.M.29 Oct 2026 · Company Update / Analyst / Investor Meet
Newspaper Publication providing extracts of Unaudited Results of Company for the quarter and half ended September 30, 2026.29 Oct 2026 · Company Update / Newspaper Publication
Press Release for Unaudited Financial Results for the quarter September 30, 202628 Oct 2026 · Company Update / Investor Presentation
Press Release for Unaudited Financial Results for the quarter ended September 30, 2026.28 Oct 2026 · Company Update / Press Release / Media Release
Unaudited Financial Results (Standalone & Consolidated for the quarter and half year ended September 30, 2026.28 Oct 2026 · Result / Financial Results
Outcome of Board Meeting held on October 28, 2026 along with Unaudited Financial Results(Standalone & Consolidated) for the quarter and half year ended September 30, 202628 Oct 2026 · Board Meeting / Outcome of Board Meeting
Intimation of Analysts/Investors Conference Call21 Oct 2026 · Company Update / Analyst / Investor Meet
Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 ,inter alia, to consider and approve Unaudited Financial ....21 Oct 2026 · Board Meeting / Board Meeting
Certificate in terms of Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 20269 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Subsequent to fulfilment of the Conditions Precedent under the BTA the transactions has been consummated with effect from today i.e. October 01, 2026.1 Oct 2026 · Company Update / Acquisition
Newspaper Advertisement regarding transfer of Shares to IEPF and Notice of loss of share Certificate30 Sep 2026 · Company Update / Newspaper Publication
Allotment of 101825 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan 202230 Sep 2026 · Company Update / Allotment of ESOP / ESPS
Closure of Trading window for the quarter and six months ended September 30, 2026.25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Press Release on Acquisition of Wellness Portfolio of Group pharmaceuticals Limited23 Sep 2026 · Company Update / Press Release / Media Release
Acquisition of the Wellness Portfolio of Group Pharmaceuticals Limited.23 Sep 2026 · Company Update / Acquisition
Voting Result and scrutinizer Report of 47th Annual General Meeting.21 Sep 2026 · AGM/EGM / AGM
Summary of Proceedings of 47th Annual General Meeting.18 Sep 2026 · AGM/EGM / AGM
Newspaper Publication for dispatch of Notice of 47th Annual General Meeting, Annual Report 2025-26 and e-voting28 Aug 2026 · Company Update / Newspaper Publication
Notice of 47th of Annual General Meeting and Annual Report for F.Y. 2025-2627 Aug 2026 · AGM/EGM / AGM
BRSR for the Financial year ended March 31, 202627 Aug 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual report for Financial Year 2025-2627 Aug 2026 · Others / Reg. 34 (1) Annual Report
Letter providing a web link of annual report 2025-26 to members.27 Aug 2026 · Company Update / General
Allotment of 27950 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee stock option Plan 202224 Aug 2026 · Company Update / Allotment of ESOP / ESPS
Newspaper Advertisement- 47th Annual General Meeting of the Company to be held on September 18, 202612 Aug 2026 · Company Update / Newspaper Publication
Earning Call Transcript for meeting held on July 30, 20264 Aug 2026 · Company Update / Earnings Call Transcript
Audio Recording of Jagsonpal Pharmaceuticals Limited Q1 FY27 Earnings Conference Call on July 30, 2026 at 2:30 P.M.30 Jul 2026 · Company Update / Analyst / Investor Meet
Newspaper Publication of Unaudited Financial Results of the Company for the quarter ended June 30, 202630 Jul 2026 · Company Update / Newspaper Publication
Change in Senior Management personnel of the Company29 Jul 2026 · Company Update / Change in Management
Corporate Action- Record Date for dividend Purpose: September 04, 202629 Jul 2026 · Corp. Action / Record Date
Intimation for grant of Employee Stock Options29 Jul 2026 · Company Update / Allotment of ESOP / ESPS
Press Release for Unaudited Financial results for quarter ended June 30, 202629 Jul 2026 · Company Update / Press Release / Media Release
Press Release for Unaudited Financial Results for quarter ended June 30, 202629 Jul 2026 · Company Update / Investor Presentation
Unaudited results along with its Limited Review Report for the quarter ended June 30, 202629 Jul 2026 · Result / Financial Results
Outcome of Board Meeting held on July 29, 2026 along with Unaudited (Standalone) Financial Results for the quarter June 30, 202629 Jul 2026 · Board Meeting / Outcome of Board Meeting
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company, as a ....22 Jul 2026 · Company Update / Analyst / Investor Meet
Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 ,inter alia, to consider and approve the unaudited Financial ....22 Jul 2026 · Board Meeting / Board Meeting
Updates on Acquisition of Aequitas Healthcare Private Limited.17 Jul 2026 · Company Update / General
Allotment of 94,000 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022.15 Jul 2026 · Company Update / Allotment of ESOP / ESPS
Updates on Acquisition of Aequitas Healthcare Private Limited8 Jul 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 4.0000	4 Sep 2026	4 Sep 2026	—
Buy Back of Shares	4 May 2026	4 May 2026	—
Final Dividend - Rs. - 2.5000	12 Sep 2025	12 Sep 2025	—
Stock Split From Rs.5/- to Rs.2/-	8 Jan 2025	8 Jan 2025	—
Final Dividend - Rs. - 5.0000	6 Sep 2024	6 Sep 2024	—

Board meetings

28 Oct 2026 Board Meeting - Financial Results
29 Jul 2026 Board Meeting - Financial Results